Burkitt Lymphoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Burkitt Lymphoma – Drugs In Development, 2023’, provides an overview of the Burkitt Lymphoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma
- The report reviews pipeline therapeutics for Burkitt Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Burkitt Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Burkitt Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Burkitt Lymphoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Burkitt Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Burkitt Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Achelois BioPharma IncAugust Pi i Sunyer Biomedical Research Institute
Aurigene Oncology Ltd
Autolus Therapeutics Plc
AVM Biotechnology LLC
Beijing zhikangbo Medical Oncology Research Co Ltd
BioCurate Pty Ltd
BioPact Ventures LLC
Biosyngen Pte Ltd
Bristol-Myers Squibb Co
Ceptur Therapeutics Inc
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
GSK plc
GT Biopharma Inc
Hebei Senlang Biotechnology Co Ltd
Huazhong University of Science & Technology
Iksuda Therapeutics Ltd
Immunitas Therapeutics Inc
JN Biosciences LLC
Karyopharm Therapeutics Inc
Kintor Pharmaceutical Ltd
Meabco AS
Medical College of Wisconsin
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Mustang Bio Inc
Nanchang University Affiliated Hospital One
National Cancer Institute US
National Center for Cardiovascular Research Carlos III
Nektar Therapeutics
Novartis AG
Orano Med LLC
Oxcia AB
Pacylex Pharmaceuticals Inc
PeproMene Bio Inc
Regeneron Pharmaceuticals Inc
Sian Wuhan Medical Technology Co Ltd
Sichuan University
Sorrento Therapeutics Inc
Stanford University
Sutro Biopharma Inc
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Co Ltd
Third Military Medical University
UNC Lineberger Comprehensive Cancer Center
University of Colorado Denver
University of Texas MD Anderson Cancer Center
UTC Therapeutics Inc
UWELL Biopharma Inc
Vincerx Pharma Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xuzhou Medical University
Y-mAbs Therapeutics Inc
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd